Zobrazeno 1 - 10
of 219
pro vyhledávání: '"Sharon, Mates"'
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 10/30/2024.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 04/16/2024.
Autor:
Trisha Suppes, Suresh Durgam, Susan G. Kozauer, Richard Chen, Hassan D. Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre, Mauricio Tohen
Publikováno v:
Bipolar Disorders.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::782c8b69f8de58be03b94a3fd3503c74
https://doi.org/10.1111/bdi.13310
https://doi.org/10.1111/bdi.13310
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 08/07/2024.
Publikováno v:
CNS Spectrums. 28:233-233
IntroductionApproved therapeutics for bipolar depression are associated with a range of undesirable side effects. Lumateperone (LUMA), a mechanistically novel antipsychotic that simultaneously modulates serotonin, dopamine, and glutamate neurotransmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d00558c680c1c0d35c73487d37db0a09
https://doi.org/10.1017/s1092852923001591
https://doi.org/10.1017/s1092852923001591
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 05/17/2023.
Autor:
Kimberly E. Vanover, Joseph R. Calabrese, Robert E. Davis, Andrew Satlin, Gary S. Sachs, Richard Chen, Suresh Durgam, Susan Kozauer, Sharon Mates
Publikováno v:
The American journal of psychiatry. 178(12)
In a phase 3 randomized double-blind placebo-controlled study, the authors investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or bipolar II disorder experiencing a major depressive episode.Patients 18-75 year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0521b15b4dda1f43674dd26afab85f3b
https://pubmed.ncbi.nlm.nih.gov/36048493
https://pubmed.ncbi.nlm.nih.gov/36048493
Autor:
Kimberly E. Vanover, Sharon Mates, John M. Kane, Andrew Satlin, Richard Chen, Robert C. Davis, Suresh Durgam
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::808100a3fdcc4714e07c02ea5c7f8ad5
https://pubmed.ncbi.nlm.nih.gov/34054112
https://pubmed.ncbi.nlm.nih.gov/34054112
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 01/09/2024.